EpicentRx Receives Fast Track Designation from the U.S. FDA for Lead Asset, RRx-001, to Prevent/Attenuate Chemotherapy and Radiation Treatment Induced Severe Oral Mucositis

by EpicentRx | Mar 29, 2023 | 2023, Press Releases

FDA also accepts company’s Investigational New Drug (IND) application to initiate a follow-on phase 2b clinical trial, called KEVLARx TORREY PINES, CA, March 29, 2023 — EpicentRx, Inc. (“EpicentRx”), announced today that the U.S. Food and Drug Administration...

Noice or Not Noice

by EpicentRx | Mar 28, 2023 | Blog

From https://www.wikihow.com/Speak-With-an-Australian-Accent Noice is the Australization of the word that the rest of the English-speaking world pronounces (more or less) as “nice”. See previous blog post entitled, “How (Not) to Speak Australian” for a link to a...

Pseudoscience: Don’t Get Fooled Again

by EpicentRx | Mar 28, 2023 | Blog

“The scientific theory I like best is that the rings of Saturn are composed entirely of lost airline luggage”. This is from Mark Russell, the famous satirist and “scientific” theorist.  Another theory, ours, is that Jupiter, the ‘romantic’ gravitational ‘partner’ of...

Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient

by EpicentRx | Mar 28, 2023 | Media

EpicentRx To Present at International Symposium on the Neuroprotective Effects of RRx-001 in Alzheimer’s and Parkinson’s diseases in Multiple Disease Models

by EpicentRx | Mar 28, 2023 | 2023, Press Releases

TORREY PINES, Calif., March 28, 2023 — EpicentRx, Inc. (“EpicentRx”), a leading-edge, clinical-stage biopharmaceutical company, has been selected for a symposium presentation at AD/PD 2023, an International Conference on Alzheimer’s & Parkinson’s...